Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This is the post-marketing study conducted in two countries: Croatia and Serbia. In both
countries Zemplar (paricalcitol) is the first injectable form of any Vitamin D Receptor (VDR)
activator available for chronic kidney disease patients on hemodialysis. The evaluation of
outcomes of VDR activator treatments in clinical practice is a major challenge in the
management of this patient population. The aim of this post-marketing observational study is
to obtain further data on the outcomes of Zemplar Injection administration during routine
clinical use.